Table 3

Associations between DAS28 components and SF-36 PCS and MCS at final trial time points

DAS28 component	CARDERA				TACIT
	Model 1: DAS28 components tested individually		Model 2: DAS28 components tested in same model		Model 1: DAS28 components tested individually		Model 2: DAS28 components tested in same model
	Standardised β (SE)	p Value	Standardised β (SE)	p Value	Standardised β (SE)	p Value	Standardised β (SE)	p Value
PCS
SJC	−0.45 (0.04)	<0.001	−0.19 (0.05)	<0.001	−0.24 (0.07)	<0.001	−0.06 (0.08)	0.412
TJC	−0.33 (0.04)	<0.001	0.00 (0.05)	0.977	−0.33 (0.07)	<0.001	−0.08 (0.09)	0.370
ESR	−0.13 (0.05)	0.005	−0.08 (0.04)	0.036	−0.02 (0.07)	0.804	0.03 (0.07)	0.676
PtGA	−0.57 (0.04)	<0.001	−0.45 (0.05)	<0.001	−0.43 (0.06)	<0.001	−0.36 (0.08)	<0.001
MCS
SJC	−0.29 (0.04)	<0.001	−0.12 (0.06)	0.029	−0.16 (0.07)	0.024	0.05 (0.08)	0.527
TJC	−0.13 (0.05)	0.004	0.15 (0.05)	0.003	−0.34 (0.07)	<0.001	−0.16 (0.09)	0.080
ESR	−0.14 (0.05)	0.004	−0.12 (0.04)	0.008	−0.04 (0.07)	0.578	0.00 (0.07)	0.974
PtGA	−0.44 (0.04)	<0.001	−0.43 (0.05)	<0.001	−0.41 (0.06)	<0.001	−0.33 (0.08)	<0.001

All linear regression models include age, gender, disease duration and treatment as covariates; CARDERA model includes the 24-month PCS and MCS as the response variables; TACIT model includes the 12-month PCS and MCS as the response variables; the VIFs were <2 for all explanatory variables in model 2. DAS28, disease activity score; ESR, erythrocyte sedimentation rate; MCS, mental component summary; PCS, physical component summary; PtGA, patient global assessment of disease activity; SF-36, Short-Form 36; SJC, swollen joint count; TJC, tender joint count.